Dynavax Reports Interim Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Squamous Cell Carcinoma of the Head and Neck

World News: . []

BERKELEY Calif April 16 2018 GLOBE NEWSWIRE -- Dynavax Technologies Corporation NASDAQDVAX today announced data from its ongoing Phase 1b2 study investigating SD-101, Dynavaxs intratumoral TLR9 agonist in combination with KEYTRUDAreg , an a...

More news and information about Dynavax Technologies Corporation

Published By:

Globe Newswire: 19:10 GMT Monday 16th April 2018

Published: .

Search for other references to "dynavax" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Ground Floor Offices, Little Keep Gate, Barrack Road, Dorchester, Dorset DT1 1AH
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us